NICE has cleared the way for bevacizumab to be used by the NHS to treat colorectal cancer for the first time, thanks to the availability of lower-cost biosimilar versions of the drug. In recently ...
National Institute for Health and Care Excellence (NICE) has today published final draft guidance recommending bevacizumab with chemotherapy for people with advanced bowel cancer. It means that more ...
Thousands more people with advanced bowel cancer to benefit as NICE approves bevacizumab biosimilars
NICE has today published final draft guidance recommending bevacizumab with chemotherapy for people with metastatic colorectal cancer. This is the first time NICE has been able to recommend ...
JSKN003 received breakthrough therapy designation for treating platinum-resistant ovarian, peritoneal, and fallopian tube cancers with HER2 expression. Clinical trials showed a 63% objective response ...
During a live event, Christine M. Parseghian, MD, examined the key trials guiding treatment selection for a patient who received 2 prior lines of therapy for metastatic colorectal cancer. Treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback